爵士製藥 JAZZ 深 滬
等待開盤 06-25 09:30:00 美东时间
229.85
-0.400
-0.17%
華盛通- 最 高234.0791
- 今 開229.76
- 成交量 71.99万股
- 最 低 228.295
- 昨 收 230.25
- 總市值 144.39亿
- 52周最高 243.32
- 市盈率 靜 --
- 換手率 1.15%
- 52周最低 105.00
- 委 比 -56.44%
- 總股本 6281.76万
- 歷史最高 243.32
- 量 比 0.69
- 振 幅 2.51%
- 歷史最低 31.87
- 每 手 1
- 風險率 38.24%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jazz Pharmaceuticals（JAZZ）拓展与AbCellera的合作 Zepzelca临床试验未达目标
爵士制药（纳斯达克：JAZZ）宣布两项核心动态，一是扩展与AbCellera的合作，共同开发针对胃肠道肿瘤及其他实体瘤的新一代T细胞双特异性抗体；二是公布Ze...
06-24 21:06
AbCellera, Jazz Partner on Next-Generation Cancer Antibodies
AbCellera Biologics ( ($ABCL) ) has issued an update. On June 17, 2026, Jazz Ph...
06-18 00:57
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced on Wednesday a collaboration with AbCellera Biologics Inc. (NASDAQ:ABCL) to discover next-generation T-cell-engaging multispecific antibodies. • Jazz Pharmaceuticals stock is showing positive momentum. What’s ahead for JAZZ stock? This partnership inc...
06-18 00:54
Jazz, AbCellera in deal to develop T-cell engaging multispecific antibodies
Jazz Pharmaceuticals (JAZZ) and AbCellera (ABCL) have inked an agreement that could be worth up to $848M to the latter company to develop next-generation T-cell engaging multispecific antibodies. The ...
06-17 19:47
Jazz Pharma announces late-stage trial setback for lung cancer therapy
Jazz Pharmaceuticals (JAZZ) traded lower in the premarket on Friday after announcing that its lung cancer therapy Zepzelca (lurbinectedin), developed with Spanish pharma company Pharma Mar (PHMMF), fa...
06-12 20:30
美股大行评级 | 高盛上调美光科技目标价从400美元升至900美元；斯马克、Cloudflare获多家公司上调目标价
今日重点评级关注：Ascendiant Capital：维持NextTrip"买入"评级，目标价从7美元升至7.5美元；Maxim Group：维持Zevra Therapeutics"买入"评级，目标价从25美元升至35美元
06-11 09:55
美股盘后 | ICON Plc涨10.66%，杜邦涨2.64%
ICON Plc涨10.66%；杜邦涨2.64%；Madison Air Solutions Corp. Class A涨1.92%
06-11 06:10
Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst
Jazz Pharmaceuticals PLC's (NASDAQ:JAZZ) revenue growth and stock valuation is being driven by the adoption of Ziihera as a first-line (1L) treatment of HER2-positive (HER2+) metastatic gastroesophageal adenocarcinoma (GEA), according to BofA Securities. • Jazz Pharmaceuticals stock is trading at el...
06-11 00:44
Shares of pharmaceutical companies are trading higher as investors rotate out of chips stocks and move into non-tech industries.
Shares of pharmaceutical companies are trading higher as investors rotate out o...
06-05 02:13
Jazz Pharmaceuticals To Present 21 Abstracts At SLEEP
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep
06-04 19:50
